Primary Care Perspectives: Episode 154 - Nirsevimab (Beyfortus)

• 2023

  Log in to bookmark this resource.

  Log in
• Katie Lockwood

---

Access Resources

• LectureEN
• Ask aRCie About This Resource

About

This podcast discusses a new preventative medicine called nirsevimab (Beyfortus), which is now available to protect infants and high-risk toddlers from respiratory syncytial virus (RSV). Dr. Lori Handy explains its science, safety, efficacy, side effects, administration, and proven benefits, including reduced morbidity based on clinical trials.

---

Tags

Focus Area: Infectious Disease

Audience: Physicians

Emergency Management Stage: Preparedness (Prevention / Protection)

Bundles: Nirsevimab Library

Keywords: Infant; Respiratory Syncytial Virus Infections; Respiratory Syncytial Viruses; Drug-Related Side Effects and Adverse Reactions; Antibodies, Monoclonal, Humanized

Institutions: Children's Hospital of Philadelphia

---

More like this

Why Are We Seeing Measles Outbreaks? – February 2024 News Brief 2024 · Children's Hospital of Philadelphia Measles Outbreak: Vital Updates for Your Practice 2024 · Children's Hospital of Philadelphia, Centers for Disease Control and Prevention (CDC), Hofstra University, WebMD Preventing RSV in Babies: A Scientific Milestone 2023 · Children's Hospital of Philadelphia

---

The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

---